Press Releases for SPPI

Press Releases
SpePharm Announces the Acquisition of Savene® from TopoTarget, an â‚¬11 Million New Round of Financing, and a Strategic Partnership with Paladin Labs, Inc
Allergan Reports Fourth Quarter 2009 Operating Results
Spectrum Pharmaceuticals Added to NASDAQ Biotechnology Index
Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008
Spectrum Pharmaceuticals Receives $50 Million From Institutional Investors at $7.55 Per Share
Spectrum Pharmaceuticals to Raise Up to $50 Million From Institutional Investors at $7.55 Per Share
BenchmarkJournal.Com Free Analyst Review for ADCT, LEAP, PLCM, SPPI, DTV and PENN
Spectrum Pharmaceuticals Announces Second Quarter 2009 Corporate Update
Spectrum Pharmaceuticals Acquires Full Rights and Intellectual Property for RenaZorb® for All Fields of Use
Altair Nanotechnologies Reports Second Quarter 2009 Financial Results
Altairnano Assigns Renazorb(TM) and Renalan(TM) Patents to Spectrum Pharmaceuticals
Spectrum Pharmaceuticals Announces Date for Second Quarter 2009 Corporate Update and Pipeline Review Conference Call
StockPreacher.com issues Trading Outlook for Spectrum Pharmaceuticals Inc.
Spectrum Pharmaceuticals to Present at the BMO Capital Markets 2009 Focus on Healthcare Conference
FDA Designates Fast Track Status for Apaziquone (EOquin®) for Bladder Cancer
FDA Accepts for Review Spectrum’s Response on ZEVALIN as a Class 1 Submission, and Establishes September 7, 2009 as Decision Date
Spectrum Pharmaceuticals Submitted Formal Response to FDA Complete Response Letter on Wednesday, July 8, 2009
BenchmarkJournal.Com Free Analyst Review for SQM, RY, ALGT, UTIW, SPPI and LJPC
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Zevalin
Spectrum Pharmaceuticals to Raise $21 Million From Institutional Investors at $7.1525 Per Share
Spectrum Pharmaceuticals to Raise $21 Million From Institutional Investors at $7.1525 Per Share
Spectrum Pharmaceuticals to Raise $21 Million from Institutional Investors at $7.1525 Per Share
Spectrum Pharmaceuticals Added to the Russell Global®, Russell 3000® and Russell 2000® Indexes
Spectrum Pharmaceuticals Announces Results of Annual Meeting of Shareholders
Spectrum Pharmaceuticals Receives $10 Million from Two Institutional Investors at $5.83 Per Share
Spectrum Pharmaceuticals to Raise $10 Million From Institutional Investors at $5.83 Per Share, the Closing Bid Price on Friday, June 12, 2009
New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting
Spectrum Pharmaceuticals Receives $20 Million from Three Institutional Investors at $5.11 Per Share
Spectrum Pharmaceuticals to Raise $20 Million From Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009
Spectrum Pharmaceuticals Wins Arbitration with Cell Therapeutics, Inc.
Spectrum Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference
Spectrum Pharmaceuticals Announces Date for First Quarter 2009 Corporate Update and Pipeline Review Conference Call
Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
SuperNovaStockPicks.com Issues Major Market Movers Today: TXT, RKH, SPPI, SNDA, VMW, & PBY - Apr 9 2009 3:42PM
CTI Receives the Second Payment of $6.5 Million Associated With the Sale of Interest in Zevalin Joint Venture - Apr 6 2009 3:58AM
Spectrum Pharmaceuticals Announces Fiscal Year 2008 Corporate Update and Pipeline Review
Spectrum Pharmaceuticals Announces That FDA Has Accepted FUSILEV™ sNDA for Colorectal Cancer Indication
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN®, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin’s Lymphoma
Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
Spectrum Pharmaceuticals to Host Conference Call Detailing ZEVALIN Joint Venture and Near-Term Strategy - Feb 25 2009 4:25PM
Spectrum Pharmaceuticals Strengthens Management, Realigns Resources to Focus on Commercialization and Near-Term Opportunities
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC™ Joint Venture upon CTI's Fulfillment of Closing Conditions
Spectrum Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
ZEVALIN® Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study
Spectrum Pharmaceuticals and Cell Therapeutics Close Transaction to Market ZEVALIN® by Forming RIT Oncology LLC, a Joint Venture
Levoleucovorin (FUSILEV™) Listed in the NCCN Drugs & Biologics Compendium™ and NCCN Updates Clinical Practice Guidelines in Oncology™
ZEVALIN Consolidation in First-Line Therapy in Patients with Non-Hodgkin’s Lymphoma Resulted in a Progression-Free Survival of Greater Than 67 Months
ZEVALIN® Data to Be Presented at 2008 Annual Meeting of the American Society of Hematology
Spectrum Pharmaceuticals to Host Conference Call Detailing ZEVALIN Joint Venture and Near-Term Strategy - Dec 1 2008 7:30AM
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review
FUSILEV(TM) Receives Unique, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)
Spectrum Pharmaceuticals Announces Receipt of $41.5 Million from Allergan, Inc. Per Collaboration Agreement for Apaziquone Announced on October 29th
Spectrum Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Investment Conference
Spectrum Pharmaceuticals Announces Third Quarter 2008 Corporate Update and Pipeline Review Conference Call
Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
Allergan, Inc. and Spectrum Pharmaceuticals, Inc. Announce Collaboration Agreement for Apaziquone (EOquin(R))
Spectrum Pharmaceuticals to Present at Seventh Annual BIO Investor Forum
Spectrum Pharmaceuticals to Present at BIOCOM's Third Annual Investor Conference
Spectrum Pharmaceuticals to Present at the JMP Securities Focus on Healthcare Conference
Spectrum Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2008
Spectrum Pharmaceuticals Launches FUSILEV(TM)
Spectrum Pharmaceuticals to Present at the Noble Financial Mad Max Conference
Spectrum Pharmaceuticals Announces Profitable Second Quarter 2008
Spectrum Pharmaceuticals Announces Second Quarter 2008 Corporate Update and Pipeline Review Conference Call
Spectrum Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Spectrum Pharmaceuticals' Board of Directors Re-Elected at Annual Stockholders Meeting
Spectrum Pharmaceuticals Announces Expansion into Canada and Establishes Spectrum Pharma Canada, Inc.
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals to Present Phase 2 Data on Ortataxel in Breast Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 27 2008 12:56AM
Spectrum Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference - May 27 2008 12:56AM
Spectrum Pharmaceuticals Announces First Quarter 2008 Financial Results and Pipeline Update - Jun 2 2008 4:37AM
Spectrum Pharmaceuticals Announces Sale of Injectable Generic Drugs to Sagent Pharmaceuticals, Inc. - Jun 2 2008 4:37AM
Spectrum Pharmaceuticals Receives $20 Million Cash Payment from Par Pharmaceutical for Sumatriptan Injection - Jun 2 2008 4:37AM
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection - Jun 2 2008 2:00AM
Spectrum Pharmaceuticals Provides an Update on Ozarelix in BPH
Spectrum Pharmaceuticals to Provide an Update on Ozarelix in BPH on Tuesday, April 22, 2008
Spectrum Pharmaceuticals Presents Data on Lucanthone, a Novel Anticancer Drug, at the Meeting of the American Association of Cancer Research
Spectrum Pharmaceuticals Presents Data on SPI-1620, a Novel Adjunct to Chemotherapy, at the American Association of Cancer Research Meeting